Plain-English translation of NCT07164885 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new approach to radiation therapy called RAPART (Radiosensitivity-Assisted Personalized Adaptive Radiotherapy) for people with advanced non-small cell lung cancer. The study compares this personalized treatment approach to standard radiation therapy to see if it helps people live longer and keep their cancer from coming back.
Standard radiation therapy for advanced lung cancer uses the same dose for all patients, but this new treatment tailors the radiation based on how sensitive each person's individual tumor is. Researchers believe this personalized approach could improve survival and reduce how long cancer stays under control.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new personalized radiation therapy or standard radiation therapy. You will receive radiation treatments over several weeks and have regular visits to monitor your health, check how well the treatment is working, and manage any side effects. The research team will follow up with you over time to see how long you survive and whether your cancer comes back.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Sponsor
Capital Medical University
Enrollment target
~911 participants
Started
February 2025
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Feng-Ming (Spring) Kong
Capital Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.